Daxor Corporation (DXR)
NASDAQ: DXR · Real-Time Price · USD
13.47
+0.47 (3.62%)
Oct 29, 2025, 12:39 PM EDT - Market open
Daxor Revenue
Daxor had revenue of $18.35K in the half year ending June 30, 2025, a decrease of -77.34%. This brings the company's revenue in the last twelve months to $66.31K, down -57.00% year-over-year. In the year 2024, Daxor had annual revenue of $119.71K, down -26.75%.
Revenue (ttm)
$66.31K
Revenue Growth
-57.00%
P/S Ratio
977.26
Revenue / Employee
$1,473
Employees
45
Market Cap
67.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 119.71K | -43.71K | -26.75% |
| Dec 31, 2023 | 163.42K | -68.22K | -29.45% |
| Dec 31, 2022 | 231.64K | -46.45K | -16.70% |
| Dec 31, 2021 | 278.09K | 13.65K | 5.16% |
| Dec 31, 2020 | 264.44K | -115.70K | -30.44% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
DXR News
- 8 days ago - Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit - GlobeNewsWire
- 4 weeks ago - Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA - GlobeNewsWire
- 5 weeks ago - Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting - GlobeNewsWire
- 7 weeks ago - Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care - GlobeNewsWire
- 2 months ago - Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter - GlobeNewsWire
- 2 months ago - Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System - GlobeNewsWire
- 3 months ago - Daxor's Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions - GlobeNewsWire